A group of Belgian researchers has retracted two decade-old papers in Arthritis & Rheumatism following an investigation and court case.
The papers involved the use of the drug infliximab — sold by Johnson & Johnson as Remicade — to treat Sjögren’s syndrome, an auto-immune condition marked by the destruction of exocrine glands that secrete saliva and tears.
Infliximab is not approved for Sjögren’s. Although the two now-retracted studies suggested that it might be helpful, subsequent data did not support those findings.
Neither, apparently, did the studies themselves. Here’s the retraction notice (it’s a PDF): Continue reading Authors retract two papers on Remicade following legal battles